HeyJaredTraci Vitek
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 15, 2026
- Outlet visibility, for Mondaq
- Top 500K sites
- Earliest in this view
- Aug 5, 2026
Latest articles
FemTech’s Real Test: Can Innovation Solve Rural America’s Maternal Health Crisis? (opens the original)
Read excerpt
"FemTech" is shorthand for a fast-growing category of technology built specifically for women's health. Once mostly period-tracking apps, it now spans regulated diagnostics, AI-driven risk prediction, and evidence-based therapeutics. In Women's Health at a Turning Point, we described federal policy finally catching up to that shift. That maturation matters well beyond investors and regulators. It is arriving just as the U.S. maternal health system faces collapse especially in rural and medically
The OPO Rule And Your Hospital's Business Model (opens the original)
Read excerpt
The US Department of Health and Human Services (HHS) is rebuilding the Organ Procurement and Transplantation Network (OPTN) system on a compressed timeline, and the changes reach past a transplant program's four walls into every donor hospital's emergency department, ICU, and compliance office. For hospitals on either side of the Organ Procurement Organization (OPO) relationship, including those that refer potential donors and those that transplant the organs those donors provide, this represent
340B Rebates 2.0: HRSA Revives Its Pilot Program — And Sets Up A Collision Course With Congress (opens the original)
Read excerpt
The Trump administration advances a claims-based rebate model for select 340B drugs as a new bipartisan Senate bill would block it, forcing health systems to track three reform paths at once. Below we review what has changed in the revised pilot, how industry has reacted, and, critically, how a brand-new bipartisan Senate bill introduced just days later is now positioned to override the administration's approach entirely. For health systems, the upshot is that 340B reform is no longer a single s
Women’s Health At A Turning Point: What Federal Policy Changes Mean For The FemTech Industry (opens the original)
Read excerpt
For decades women's health has too often been treated as a narrow policy category, despite affecting roughly half the population. That is changing. There is now an emerging category of medicine built around regulated software, biomarker-based decision-making, and new regulatory and reimbursement pathways. FemTech now spans menstrual health, fertility, pregnancy and postpartum care, pelvic and sexual health, menopause, contraception, and conditions that affect women differently or disproportionat
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Mondaq, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.